Taken together, our results here, in mice, and from our previous work in PD cells in vitro provide evidence that targeting LRRK2 exon 41 splicing with ASOs has a therapeutic effect on pathogenic LRRK2 expression and thus may be a promising drug candidate for treating PD in humans. Here, LRRK2 is linked to Parkinson disease.